- Y Diweddaraf sydd Ar Gael (Diwygiedig)
- Pwynt Penodol mewn Amser (25/05/2007)
- Gwreiddiol (a wnaed Fel)
Version Superseded: 06/03/2018
Point in time view as at 25/05/2007.
There are currently no known outstanding effects for the The Human Tissue (Quality and Safety for Human Application) Regulations 2007.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
Regulation 7
1. The Authority may on application grant a licence for the purposes of regulation 7.U.K.
2. A licence under this Schedule may authorise the carrying-on of any of the activities to which regulation 7(1) or (2) applies.U.K.
3. A licence—U.K.
(a)shall designate an individual as the designated individual, and
(b)shall not authorise the licensed activities to be carried on under the supervision of more than one such individual.
4. A licence —U.K.
(a)shall specify the premises (other than relevant third party premises) where the licensed activity is authorised to be carried on, and
(b)shall not authorise the licensed activity to be carried on on premises (other than relevant third party premises in the case of activities to which regulation 7(2) applies) at different places.
5. It shall be a condition of a licence under this Schedule—U.K.
(a)that the licensed activities shall be carried on only under the supervision of the designated individual;
(b)that the licensed activity shall be carried on only on the premises specified in the licence or, in the case of activities to which regulation 7(2) applies, on relevant third party premises.
6. In determining the amounts of any fees to be charged under paragraph 13 of Schedule 3 to the 2004 Act, as applied by regulation 8, the Authority shall have regard to its costs in connection with the consideration of applications for licences under this Schedule.U.K.
Regulation 16
1. Directions shall require that licence holders adopt such systems as the Authority considers appropriate to secure—U.K.
(a)in relation to traceability, compliance with the requirements of Article 8 (traceability) of the first Directive and Article 9 (traceability) of the third Directive; and
(b)in relation to the coding of information, compliance with the requirements of Article 25 (coding of information) of the first Directive and Article 10 (European coding system) of the third Directive.
2. Directions given for the purposes of paragraph 1 shall include directions requiring designated individuals to ensure that third parties responsible for human application retain the information listed in Annex VI (information on the minimum donor/recipient data set to be kept) and Annex VII (information contained in the European coding system) to the third Directive.U.K.
3. Directions under paragraph 2(4)(c) to (e) of Schedule 3 to the 2004 Act (as applied by regulation 8) shall specify the information to be recorded, the form in which it is to be recorded, the period for which such information is to be kept and the persons to whom any specified information is to be provided for the purpose of securing compliance with the requirements of Article 10(1) (register of tissue establishments and reporting obligations) of the first Directive.U.K.
4. Directions shall require licence holders to adopt such—U.K.
(a)systems to report, investigate, register and transmit information about serious adverse events and serious adverse reactions, and
(b)accurate, rapid and verifiable procedures for recalling from distribution any product which may be related to a serious adverse event or serious adverse reaction,
as are necessary to secure compliance with the requirements of Article 11 (notification of serious adverse events and reactions) of the first Directive and Article 5 (notification of serious adverse reactions) and Article 6 (notification of serious adverse events) of the third Directive.
5. For the purpose of securing compliance with the requirements of Article 21(5) (tissue and cell storage conditions) and Article 24 (relations between tissue establishments and third parties) of the first Directive, directions shall specify the requirements that must be met in relation to the termination of storage activities authorised by the licence and in relation to third party agreements.U.K.
6. Directions shall specify the requirements to be met by all licence holders authorised to procure tissue or cells to secure compliance with the requirements (including as to staff training, written agreements with staff, standard operating procedures, and appropriate facilities and equipment) laid down in Article 2 (requirements for the procurement of human tissues and cells) of the second Directive.U.K.
7. Directions shall be given—U.K.
(a)for the purpose of securing that procurement organisations comply with the requirements of the Annex to the first Directive (information to be provided on the donation of tissue or cells), and
(b)for the purpose of securing that procurement organisations and organisations responsible for human application of tissue or cells comply with the requirements of Article 5 (notification of serious adverse reactions) and Article 6 (notification of serious adverse events) of the third Directive.
8. In giving directions for the purposes of paragraph 7, the Authority shall, in particular, impose a requirement on designated individuals to ensure that records are retained, and the Authority and tissue establishments are notified without delay, of any serious adverse event and any serious adverse reaction.U.K.
9. In relation to donors of tissues or cells who are deceased at the time of donation, directions shall impose requirements in respect of the selection criteria for such donors, in accordance with—U.K.
(a)in relation to all such donors, point 1.1 (general criteria for exclusion), and
(b)in relation to such donors who are children, point 1.2 (additional exclusion criteria for deceased child donors),
of Annex I (selection criteria for donors of tissue or cells) to the second Directive.
10. In relation to donors of tissues or cells who are alive at the time of donation, directions shall impose requirements in respect of the selection criteria for such donors, in accordance with—U.K.
(a)in relation to autologous donors, point 2.1 (autologous living donor),
(b)in relation to allogeneic donors, point 2.2 (allogeneic living donor),
of Annex I to the second Directive.
11. Directions shall, in respect of all donors of tissues or cells, deal with the biological tests to be performed and carried out, in accordance with the requirements of section 1 (biological tests required for donors) and section 2 (general requirements to be met for determining biological markers) of Annex II (laboratory tests required for donors) to the second Directive.U.K.
12. In respect of—U.K.
(a)donation and procurement procedures, and
(b)the reception of tissue and cells at premises specified in a licence under Schedule 1,
directions shall be given for the purpose of securing compliance with the requirements of Article 15(3) (selection, evaluation and procurement) and Article 19(4) to (6) (tissue and cell reception) of the first Directive and with the requirements laid down in the provisions of the second Directive listed in the right-hand column, the subject-matter of which are described in the left-hand column in respect of those provisions.
Relevant provisions of the second Directive | |
---|---|
1. Donation and procurement procedures | |
Consent and donor identification (record of consent, method of identification, donor interview) | Annex IV, point 1.1 |
Donor evaluation: other than autologous donors (assessment of donor's medical and behavioural information and physical examinations) | Annex IV, point 1.2 |
Procurement procedures for tissue and cells (requirements relating to procurement procedures and instruments) | Annex IV, point 1.3 |
Donor documentation (record of donor and the procurement) | Annex IV, point 1.4 |
Packaging (requirements as to packaging and shipping containers) | Annex IV, point 1.5 |
Labelling of the procured tissue and cells (minimum labelling requirements) | Annex IV, point 1.6 |
Labelling of the shipping container (minimum labelling requirements) | Annex IV, point 1.7 |
2. Reception of tissue and cells at the tissue establishment | |
Verification upon arrival (procedures for verification and requirement for quarantine until verification) | Annex IV, point 2.1 to 2.3 |
Registration of data | Annex IV, point 2.4 |
13. Directions shall be given for the purpose of securing compliance with the requirements laid down in the provisions of the third Directive listed in the right-hand column, the subject-matter of which are described in the left-hand column in respect of those provisions.U.K.
Relevant provisions of the third Directive | |
---|---|
Organisation and management (requirements as to organisational structure, management systems, and third party agreements) | Annex I, Part A |
Personnel (number, competence, responsibilities and training) | Annex I, Part B |
Equipment and materials (appropriate for use, validation, maintenance, and specifications) | Annex I, Part C |
Facilities and premises (suitability, environment, storage, and maintenance) | Annex I, Part D |
Documentation and records (standard operating procedures, document control, record reliability) | Annex I, Part E |
Quality review (quality management system, investigations, corrective action, and reviews) | Annex I, Part F |
14. In respect of tissue and cell preparation processes, directions shall be given for the purpose of securing compliance with—U.K.
(a)the requirements of Article 20(2) and (3) (tissue and cell processing) and Article 21(2) to (4) of the first Directive, and
(b)the requirements laid down in the provisions of the third Directive listed in the right-hand column, the subject-matter of which are described in the left-hand column in respect of those provisions.
Relevant provisions of the third Directive | |
---|---|
Reception of tissue and cells at the tissue establishment | Annex II, Part A |
Processing of tissue and cells (validation, documentation and evaluation of critical procedures) | Annex II, Part B |
Storage and release of tissue and cells (criteria to be complied with, including standard operating procedure) | Annex II, Part C |
Distribution and recall of tissue and cells (criteria to be complied with, including procedures to be adopted) | Annex II, Part D |
Final labelling of tissue and cells containers for distribution (information to be shown on container label or in accompanying documentation) | Annex II, Part E |
External labelling of the shipping container (information to be shown on label on shipping container) | Annex II, Part F |
Regulation 24
An appropriate statement for the purposes of regulation 24 must contain the following information—
(a)a statement that the duly authorised person has been authorised by the Authority for the purposes of regulation 23;
(b)a statement that the duly authorised person's rights of entry and search are subject to his producing evidence of his entitlement to exercise them, if required;
(c)a statement that the duly authorised person is entitled, if need be, to enter the premises by force;
(d)a description of the duly authorised person's powers under regulation 25(2) to (4) of inspection and seizure of property;
(e)a description of the requirement under paragraph 25(5) for the duly authorised person to leave a statement giving particulars of what he has seized and stating that he has seized it;
(f)a description of the powers of the duly authorised person—
(i)under regulation 26(1), to bring with him such other persons and equipment as he considers necessary;
(ii)under regulation 26(2), to inspect equipment and inspect and take copies of records, and in the case of premises in respect of which a licence under Schedule 1 is in force, or relevant third party premises in respect of which a third party agreement is in force, to observe the carrying-on of licensed activity or activity pursuant to such agreement;
(g)a description of the duly authorised person's obligations under regulation 27(2) to prepare a written report of the search and, if requested to do so by the appropriate person, give him a copy of the report;
(h)a statement that a person commits an offence under regulation 28 if—
(i)he fails without reasonable excuse to comply with a requirement under regulation 26(3), or
(ii)he intentionally obstructs the exercise of any right under Part 5.
Y Diweddaraf sydd Ar Gael (diwygiedig):Y fersiwn ddiweddaraf sydd ar gael o’r ddeddfwriaeth yn cynnwys newidiadau a wnaed gan ddeddfwriaeth ddilynol ac wedi eu gweithredu gan ein tîm golygyddol. Gellir gweld y newidiadau nad ydym wedi eu gweithredu i’r testun eto yn yr ardal ‘Newidiadau i Ddeddfwriaeth’.
Gwreiddiol (Fel y’i Deddfwyd neu y’i Gwnaed): Mae'r wreiddiol fersiwn y ddeddfwriaeth fel ag yr oedd pan gafodd ei deddfu neu eu gwneud. Ni wnaed unrhyw newidiadau i’r testun.
Pwynt Penodol mewn Amser: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Rhychwant ddaearyddol: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Dangos Llinell Amser Newidiadau: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Mae Memoranda Esboniadol yn nodi datganiad byr o ddiben Offeryn Statudol ac yn rhoi gwybodaeth am ei amcan polisi a goblygiadau polisi. Maent yn ceisio gwneud yr Offeryn Statudol yn hygyrch i ddarllenwyr nad oes ganddynt gymhwyster cyfreithiol, ac maent yn cyd-fynd ag unrhyw Offeryn Statudol neu Offeryn Statudol Drafft a gyflwynwyd ger bron y Senedd o Fehefin 2004 ymlaen.
Gallwch wneud defnydd o ddogfennau atodol hanfodol a gwybodaeth ar gyfer yr eitem ddeddfwriaeth o’r tab hwn. Yn ddibynnol ar yr eitem ddeddfwriaeth sydd i’w gweld, gallai hyn gynnwys:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Defnyddiwch y ddewislen hon i agor dogfennau hanfodol sy’n cyd-fynd â’r ddeddfwriaeth a gwybodaeth am yr eitem hon o ddeddfwriaeth. Gan ddibynnu ar yr eitem o ddeddfwriaeth sy’n cael ei gweld gall hyn gynnwys:
liciwch ‘Gweld Mwy’ neu ddewis ‘Rhagor o Adnoddau’ am wybodaeth ychwanegol gan gynnwys